Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
Running, not enrolling · Phase 3 · Has a placebo group
Conditions studied: Systemic Sclerosis, Scleroderma
In brief
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.
Key facts
- Study ID
- NCT05925803
- Run by
- AstraZeneca
- People needed
- 314
- Starts
- 2023-11-08
- Expected to finish
- 2028-04-05
- Last updated by the study team
- 2026-07-23
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Vienna, Austria
- Research Site — Ghent, Belgium
- Research Site — Leuven, Belgium
- Research Site — Calgary, Alberta, Canada
- Research Site — Toronto, Ontario, Canada
- Research Site — Montreal, Quebec, Canada
- Research Site — Montreal, Quebec, Canada
- Research Site — Québec, Canada
- Research Site — Beijing, China
- Research Site — Beijing, China
- Research Site — Guangzhou, China
- Research Site — Guangzhou, China
- Research Site — Hangzhou, China
- Research Site — Lanzhou, China
- Research Site — Shanghai, China
- Research Site — Shanghai, China
- Research Site — Tianjin, China
- Research Site — Bordeaux, France
- Research Site — Brest, France
- Research Site — Paris, France
- Research Site — Paris, France
- Research Site — Rennes, France
- Research Site — Strasbourg, France
- Research Site — Toulouse, France
- Research Site — Innsbruck, Austria
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.